Shengzhu Huang1,2,3,4, Jiarong Tian1,2,3, Chaoqun Liu5, Yu Long6, Dehao Cao1,2,3,4, Luyun Wei1,2,3,4, Xiujuan Zhu1,2,3,4, Ruiqiang Tang1,2,3,4, Weiwu Liu7, Dingyuan Zeng8, Mujun Li9, Xiaobo Yang10,11,12,13, Zengnan Mo14,15,16,17. 1. Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, 530021, Guangxi, China. 2. Guangxi key Laboratory for Genomic and Personalized Medicine, Nanning, 530021, Guangxi, China. 3. Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Nanning, 530021, Guangxi, China. 4. School of Public Health, Guangxi Medical University, 22 Shuangyong Road, Nanning, 530021, Guangxi, China. 5. Department of Occupational Health and Environmental Health, School of Public Health of Guangxi Medical University, Nanning, 530021, Guangxi, China. 6. Department of Gynecology and Obstetrics, First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi, China. 7. Department of Obstetrics, Maternal & Child Health Hospital of Yulin, Yulin, Guangxi, China. 8. Department of Reproductive Center, First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi, China. 9. Department of Gynecology and Obstetrics, Maternal & Child Health Hospital of Liuzhou, Liuzhou, Guangxi, China. 10. Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, 530021, Guangxi, China. yangx@gxmu.edu.cn. 11. Guangxi key Laboratory for Genomic and Personalized Medicine, Nanning, 530021, Guangxi, China. yangx@gxmu.edu.cn. 12. Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Nanning, 530021, Guangxi, China. yangx@gxmu.edu.cn. 13. Department of Occupational Health and Environmental Health, School of Public Health of Guangxi Medical University, Nanning, 530021, Guangxi, China. yangx@gxmu.edu.cn. 14. Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, 530021, Guangxi, China. zengnanmo@hotmail.com. 15. Guangxi key Laboratory for Genomic and Personalized Medicine, Nanning, 530021, Guangxi, China. zengnanmo@hotmail.com. 16. Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Nanning, 530021, Guangxi, China. zengnanmo@hotmail.com. 17. Institute of Urology and Nephrology, First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi, China. zengnanmo@hotmail.com.
Abstract
BACKGROUND: Currently, there are many studies researched the associations between maternal serum inflammatory indicators (i.e. ferritin, C-reactive protein [CRP], C3 and C4) and preterm birth (PTB). The results, however, are inconsistent. Therefore, the aim of this study was to estimate the relationship between maternal serum inflammatory indicators and PTB in a nested case-control (NCC)study. METHODS: A NCC study was conducted by Guangxi Birth Cohort Study which enrolled a total of 6203 pregnant women between 50/7 and 346/7 weeks of gestational age (wGA) from six cities in China between 2015 and 2016. There were 206women who delivered preterm (< 370/7 wGA), and 412 women who delivered term birth, those women were matched by maternal age, birth place, gender of infants, and wGA at blood collection. The inflammatory indicators were quantified by immunoturbidimetric methods. RESULTS: Highest quartile concentrations of all inflammatory indicators were determined versus median. After adjusting for maternal age, high levels of CRP (CRP > 16.60 mg/L) are related to the risk of PTB (OR = 2.16, 95% CI: 1.02-4.56, p = 0.044) in the first trimester. The association of C3 was extremely related to those who delivered PTB (OR = 2.53, 95% CI: 1.14-5.64, p = 0.023) in the first trimester. Moreover, no significant associations were found in C4 (p = 0.079) and ferritin (p = 0.067) between PTB. CONCLUSIONS: Elevated concentrations of CRP and C3 in the first trimester were associated with increased risk of PTB. Inflammatory indicators may act a pivotal part in early diagnosis and prognosis of PTB.
BACKGROUND: Currently, there are many studies researched the associations between maternal serum inflammatory indicators (i.e. ferritin, C-reactive protein [CRP], C3 and C4) and preterm birth (PTB). The results, however, are inconsistent. Therefore, the aim of this study was to estimate the relationship between maternal serum inflammatory indicators and PTB in a nested case-control (NCC)study. METHODS: A NCC study was conducted by Guangxi Birth Cohort Study which enrolled a total of 6203 pregnant women between 50/7 and 346/7 weeks of gestational age (wGA) from six cities in China between 2015 and 2016. There were 206women who delivered preterm (< 370/7 wGA), and 412 women who delivered term birth, those women were matched by maternal age, birth place, gender of infants, and wGA at blood collection. The inflammatory indicators were quantified by immunoturbidimetric methods. RESULTS: Highest quartile concentrations of all inflammatory indicators were determined versus median. After adjusting for maternal age, high levels of CRP (CRP > 16.60 mg/L) are related to the risk of PTB (OR = 2.16, 95% CI: 1.02-4.56, p = 0.044) in the first trimester. The association of C3 was extremely related to those who delivered PTB (OR = 2.53, 95% CI: 1.14-5.64, p = 0.023) in the first trimester. Moreover, no significant associations were found in C4 (p = 0.079) and ferritin (p = 0.067) between PTB. CONCLUSIONS: Elevated concentrations of CRP and C3 in the first trimester were associated with increased risk of PTB. Inflammatory indicators may act a pivotal part in early diagnosis and prognosis of PTB.
Authors: Manjunath Ramanjaneya; Alexandra E Butler; Meis Alkasem; Mohammed Bashir; Jayakumar Jerobin; Angela Godwin; Abu Saleh Md Moin; Lina Ahmed; Mohamed A Elrayess; Steven C Hunt; Stephen L Atkin; Abdul-Badi Abou-Samra Journal: Front Endocrinol (Lausanne) Date: 2021-03-30 Impact factor: 5.555
Authors: Maria A Kennelly; Sarah Louise Killeen; Catherine M Phillips; Gouiri Alberdi; Karen L Lindsay; John Mehegan; Martina Cronin; Fionnuala M McAuliffe Journal: Cytokine Date: 2021-10-23 Impact factor: 3.926